Royalty Pharma plc Increase (Decrease) in Other Operating Liabilities
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Other Operating Liabilities of -$1.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-05
- Royalty Pharma plc increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was -$923.00K.
- Royalty Pharma plc increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$1.01M.
- Royalty Pharma plc increase (decrease) in other operating liabilities for the quarter ending 2025-06-30 was -$332.00K.
- Royalty Pharma plc increase (decrease) in other operating liabilities for the quarter ending 2025-03-31 was $0.00.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month |
|---|---|---|
| 2026-06-30 | -$923.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.93M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$1.01M 10-Q · filed 2026-05-06 | |
| 2025-06-30 | -$332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$332.00K 10-Q · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |